Advertisement
Table 1 Baseline demographic and disease characteristics*
| Group A (n = 49) (MTX treatment) % v. mean (SD) | Group B (n = 35) (anti-TNF + MTX treatment) % v. mean (SD) | |
|---|---|---|
| Age, (mean ± S.D.) | 60.1 (13.7) | 54.7 (15) |
| Women, n (%) | 42 (85.7%) | 28 (80%) |
| Disease duration, (month) | 7.9 (2) | 8.5 (1.2) |
| IgM RF positive, n (%) | 34 (69.4%) | 22 (62.9%) |
| Anti-CCP positive, n (%) | 37 (75.5%) | 26 (74.3%) |
| DAS28ESR , mean ± S.D. | 6.1 (0.9) | 6.4 (0.9) |
| CDAI, mean ± S.D. | 36.2 (11.5) | 33.6 (12.7) |
| Tender joint count, mean ± S.D. | 13.1 (6.5) | 14 (7.2) |
| Swollen joint count, mean ± S.D. | 7.5 (5.9) | 9.4 (5.2) |
| Patient global assessment (VAS 0–100), mean ± S.D. | 65 (17.9) | 64.3 (18.3) |
| ESR, mean ± S.D. | 43.7 (22.4) | 46.9 (33.5) |
| CRP, mean ± S.D. | 27.5 (28.4) | 40.3 (46.9) |
| HAQ-DI (0–3), mean ± S.D. | 1.4 (0.7) | 1.6 (0.7) |
